We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+36.64%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$1.35B
AUM Growth
+$446M
Cap. Flow
+$266M
Cap. Flow %
19.74%
Top 10 Hldgs %
44.95%
Holding
104
New
31
Increased
29
Reduced
24
Closed
13

Top Buys

Rank Stock Value
1
TGTX icon
TG Therapeutics
TGTX
+$40.1M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$34.3M
3
ONC
BeOne Medicines Ltd
ONC
+$23.8M
4
BIIB icon
Biogen
BIIB
+$17M
5
KROS icon
Keros Therapeutics
KROS
+$16.2M

Top Sells

Rank Stock Value
1
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$46.4M
2
GSK icon
GSK
GSK
+$39.6M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$26.2M
4
MREO
Mereo BioPharma
MREO
+$24.2M
5
VKTX icon
Viking Therapeutics
VKTX
+$16.4M

Sector Composition

Rank Sector Weight
1 Healthcare 84.45%
2 Consumer Staples 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XENE icon
101
Xenon Pharmaceuticals
XENE
$6.1B
– –
-58,000
Closed -$2.67M
RYZB
102
DELISTED
RayzeBio, Inc. Common Stock
RYZB
– –
-746,622
Closed -$46.4M
IMGN
103
DELISTED
Immunogen Inc
IMGN
– –
-13,050
Closed -$387K
HARP
104
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
– –
-820,638
Closed -$9.33M
1 2 3 4
5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return
QT
Quantbot Technologies New York $2.44B AUM 17.13% 1-Year Est. Return

Soleus Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, Soleus Capital Management held 104 positions worth $1.35B, up 50% from $901M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Soleus Capital Management deployed $266M of net new capital in Q1 2024, opening 31 new positions and adding to 29 existing holdings. Its largest new stake was BeOne Medicines Ltd: 148,100 shares worth $23.2M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 100% a quarter earlier, followed by Consumer Staples.

On the sell side, the largest reduction was GSK, an estimated $39.6M trimmed.

  • Soleus Capital Management's largest Q1 2024 buy was BeOne Medicines Ltd: 148,100 shares worth $23.2M.
  • Soleus Capital Management added most to TG Therapeutics in Q1 2024, an estimated $40.1M increase.
  • Soleus Capital Management's biggest Q1 2024 reduction was GSK, cutting an estimated $39.6M.
  • Soleus Capital Management fully exited RayzeBio, Inc. Common Stock in Q1 2024, selling an estimated $46.4M.
  • Soleus Capital Management's ten largest holdings make up 45% of its $1.35B portfolio in Q1 2024.
  • Soleus Capital Management opened 31 new positions and closed 13 in Q1 2024.
  • Soleus Capital Management's portfolio value rose 50% quarter-over-quarter to $1.35B.

Based on Soleus Capital Management's 13F filing for Q1 2024, filed 15 May 2024.